Tata Nifty MidSmall Healthcare Index Fund
In plain words
as of 20 Nov 2026This fund does not have enough history yet for a reading. Most numbers need at least a year, risk numbers need three.
Key facts
- Fund house
- Tata Mutual Fund
- Category
- Index Funds (Equity) (SEBI)
- Plan & option
- Regular · IDCW
- Benchmark i
- None used for this category
- First NAV
- 30 Apr 2024 · — of history · 631 NAVs
- AMFI code
- 152563
- ISIN
- — · INF277KA1BF5 (reinvest)
- Expense ratio i
- 1.15%
- Fund size
- Not loaded yet
How ₹100 grew
Returns
Up to 1 year: total change. Longer: yearly (CAGR) i| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 7Y | 10Y | Since launch | |
|---|---|---|---|---|---|---|---|---|---|---|
| This fund | — | — | — | — | — | — | — | — | — | — |
| Index Funds (Equity) middle fund i | +8.17% | −0.17% | +5.81% | +1.26% | +0.50% | +10.76% | +8.57% | +12.10% | +12.82% | — |
Category middle = median Regular Growth fund in Index Funds (Equity) (112 funds with 3 years). Blank means not enough history, never zero.
Risk and risk-adjusted return
Last 36 months · risk-free rate 6.5%Against its benchmark
No equity benchmark for this categoryThe worst it has been
Every 1-year period i
One 5-year number depends on its start date. These show what happened across every start date in the fund's life.
What it holds
filed for 31 Oct 2026Asset mix
Company size
How concentrated
Largest sector: Pharmaceuticals & Biotechnology at 80.9%.
Largest holdings
| Holding | Sector | Weight |
|---|---|---|
| LAURUS LABS LTD | Pharmaceuticals & Biotechnology | 14.12% |
| LUPIN LTD | Pharmaceuticals & Biotechnology | 7.36% |
| AUROBINDO PHARMA LTD | Pharmaceuticals & Biotechnology | 7.00% |
| FORTIS HEALTHCARE LTD | Healthcare Services | 6.03% |
| GLENMARK PHARMACEUTICALS LTD | Pharmaceuticals & Biotechnology | 5.22% |
| ALKEM LABORATORIES LTD | Pharmaceuticals & Biotechnology | 4.65% |
| MANKIND PHARMA LTD | Pharmaceuticals & Biotechnology | 4.26% |
| IPCA LABORATORIES LTD | Pharmaceuticals & Biotechnology | 4.04% |
| GLAND PHARMA LTD | Pharmaceuticals & Biotechnology | 3.72% |
| BIOCON LTD | Pharmaceuticals & Biotechnology | 3.70% |
| SAI LIFE SCIENCES LTD | Pharmaceuticals & Biotechnology | 3.25% |
| ACUTAAS CHEMICALS LTD | Pharmaceuticals & Biotechnology | 3.13% |
| KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD | Healthcare Services | 2.82% |
| ASTER DM QUALITY CARE LTD | Healthcare Services | 2.74% |
| NEULAND LABORATORIES LTD | Pharmaceuticals & Biotechnology | 2.56% |
| AJANTA PHARMA LTD | Pharmaceuticals & Biotechnology | 2.41% |
| WOCKHARDT LTD | Pharmaceuticals & Biotechnology | 2.37% |
| DR. LAL PATH LABS LTD | Healthcare Services | 2.24% |
| PIRAMAL PHARMA LTD | Pharmaceuticals & Biotechnology | 2.24% |
| ABBOTT INDIA LTD | Pharmaceuticals & Biotechnology | 2.01% |
| GRANULES INDIA LTD | Pharmaceuticals & Biotechnology | 1.87% |
| ONESOURCE SPECIALTY PHARMA LTD | Pharmaceuticals & Biotechnology | 1.85% |
| NARAYANA HRUDAYALAYA LTD | Healthcare Services | 1.79% |
| GLOBAL HEALTH LTD | Healthcare Services | 1.70% |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD | Pharmaceuticals & Biotechnology | 1.56% |
| ANTHEM BIOSCIENCES LTD | Pharmaceuticals & Biotechnology | 1.35% |
| NATCO PHARMA LTD | Pharmaceuticals & Biotechnology | 1.16% |
| SYNGENE INTERNATIONAL LTD | Healthcare Services | 1.15% |
| COHANCE LIFESCIENCES LTD | Pharmaceuticals & Biotechnology | 1.09% |
| POLY MEDICURE LTD | Healthcare Equipment & Supplies | 0.83% |
Sectors
What the manager did last month
30 Sep 2026 → 31 Oct 2026A holding's value moves with its price; only a change in the number of shares is a decision. These lists use share counts. A split or bonus also changes share counts, so check sudden round multiples.
Added to 30
Against similar funds
Top Index Funds (Equity) Regular Growth funds by return. A sort by one past number, not a recommendation.
| Fund | Return | Volatility | Sharpe | Alpha | Beta | Deepest fall | Stars |
|---|---|---|---|---|---|---|---|
| ICICI Prudential Nifty Pharma Index Fund ICICI Pru | +20.87% | 14.9% | 0.96 | −1.16% | 1.00 | −16.78% | ★★★★★ |
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Edelweiss | +19.86% | 11.2% | 1.19 | — | — | −16.69% | ★★★★★ |
| ICICI Prudential NASDAQ 100 Index Fund ICICI Pru | +19.76% | 19.8% | 0.67 | — | — | −30.20% | ★★★★★ |
| ICICI Prudential Nifty Auto Index Fund ICICI Pru | +19.55% | 21.3% | 0.61 | −1.01% | 1.00 | −28.51% | ★★★★★ |
| Motilal Oswal BSE Enhanced Value Index Fund Motilal Oswal | +19.23% | 21.5% | 0.59 | — | — | −21.81% | ★★★★★ |
| Motilal Oswal S&P 500 Index Fund Motilal Oswal | +18.72% | 14.4% | 0.85 | — | — | −20.14% | ★★★★★ |
| Motilal Oswal BSE Enhanced Value Index Fund Motilal Oswal | +18.43% | 21.5% | 0.56 | — | — | −22.11% | ★★★★★ |
| UTI Nifty 500 Value 50 Index Fund UTI | +18.17% | 19.7% | 0.59 | — | — | −22.84% | ★★★★★ |
| Navi Nifty India Manufacturing Index Fund Navi | +16.77% | 17.2% | 0.60 | — | — | −23.35% | ★★★★★ |
| Kotak Nifty Next 50 Index Fund Kotak | +16.23% | 20.3% | 0.48 | −0.59% | 1.00 | −26.49% | ★★★★★ |
Compare side by side with another Index Funds (Equity) fund
All plans and options
| Scheme | NAV | AMFI code |
|---|---|---|
| Direct · Growth | ₹15.9406 | 152564 |
| Direct · IDCW | ₹15.9406 | 152565 |
| Direct · IDCW | ₹15.9406 | 152566 |
| Regular · Growth | ₹15.6794 | 152567 |
| Regular · IDCW | ₹15.6794 | 152562 |
| Regular · IDCW | ₹15.6794 | 152563 |
About Index Funds (Equity) funds
- The rule
- Copies an equity index such as NIFTY 50; low cost, no stock picking.
- Who it can suit
- Investors who want the market's return at low cost.
- Typical holding period
- 5 years or more
Questions people ask
What is the NAV of Tata Nifty MidSmall Healthcare Index Fund?
₹15.6794 as of 20 Nov 2026, from AMFI's daily NAV file. NAVs are published once every business day after markets close.
Direct or Regular: what is the difference?
Same portfolio. Regular pays a distributor commission inside its fee, so it returns a little less every year.
Growth or IDCW?
Growth reinvests everything. IDCW pays some out, so its NAV drops after each payout and its NAV-based return understates what investors received.
How are these numbers calculated?
Every figure is computed by Growth from the fund's published NAV history. See How we calculate.